The Catalyst

Most Recent Posts

06.27.13 | By Preet Bilinski

Recently the American Medial Association endorsed recognizing obesity as a disease. The U.S.

06.27.13 | By Jay Taylor

Today, Rep. Terry (R. NE) chairman of the House Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade held a hearing to highlight how India’s industrial policy is hurting U.S.


The Partnership to Fight Chronic Disease (PFCD) has released a thoughtful new policy paper outlining the most effective ways to lower Medicaid health care costs without compromising quality of care or patient health outcomes.


Following PhRMA CEO John Castellani's post last week, we are thrilled to announce the launch of our new forum, “Conversations.” We hope you will join the debate on as we ask some of the biggest questions in health care.

Our inaugural question is:

06.24.13 | By Stephanie Fischer

In a previous post, I shared my personal experience with stroke and encouraged readers to know the warning signs and symptoms of stroke.  A new report by PhRMA on Medicines in Development for Heart Disease and Stroke provides


As our President and CEO John Castellani emphasized, “Healthy debate is the foundation of progress and advancement.” This is something we feel very strongly about, and the initiatives announced this week show our commitment to being part of the ongoing dialogue around health care.


Dean Kamen, a great scientist and inventor, said that “we now live in a world where technology, in many ways, has triumphed over death.”  As we look at the bigger picture around the value of innovation, particularly in a cost-containment environment, we must always keep this triumph in the back of our minds. 


Last week, POLITICO sat down with President and CEO John Castellani to discuss how he is working to elevate the biopharmaceutical industry’s role as a thought leader within the health care ecosystem, as well as a key player in policy discussions within Washington and beyond.

06.18.13 | By Jay Taylor

A new alliance was launched today to begin educating the public and policymakers about the growing imbalance with the United States’ trading relationship with India and the potential consequences for American job losses if these concerns are not addressed.

06.18.13 | By John Castellani

Inventor Thomas Edison once said, “If we did all the things we are capable of, we would literally astound ourselves.”


Last week, we took another step in our fight against chronic disease by extending our successful partnership with the Women in Government Foundation, Inc. (WIG), a national non-profit, non-partisan organization of women state legislators.


The first step toward finding solutions in our health care ecosystem is to identify what works, protect what is successful and fix what isn’t. This includes access to medicines, continued research and development and developing programs that get patients the treatments they need.


Craving some health policy news on a Friday afternoon? Check out an op-ed that ran in The Hill today from our CEO, John Castellani, on Part D.

06.14.13 | By John Castellani

Science has been on my mind lately – and for two very good reasons.

06.13.13 | By Stephanie Fischer

As you may know from reading past Catalyst posts, the Prescription Drug User Fee Act (PDUFA) was reauthorized last July when the Food and Drug Safety and Innovation Act (FDASIA) was signed into law.


The Annals of Internal Medicine recently published a study that compared prescription diabetes medicine use between Medicare Part D and the Veterans Affairs (VA) program, specifically focusing on generic drug use. The study and subsequent media coverage overlook some important facts about prescription drug coverage in these two programs.

06.12.13 | By Preet Bilinski

Every 39 seconds an American dies from cardiovascular disease, and more than 83 million Americans have at least one type of the disease, the American Heart Association (AHA) reports. But today, America’s biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans – heart disease and stroke. 


Medical innovation does an enormous amount of good for patients, but there is also a broader societal impact: innovative research positively impacts the economy, as well.

06.07.13 | By Chip Davis

This week, the Commerce Department released the latest data on America’s trade balance, and the news was not good. While exports of U.S. goods and services rose in April, our trade deficit grew to $40.3 billion, up more than 8 percent in a single month.


Earlier this week, PhRMA’s Gabriela Lavezzari, Assistant Vice President, Scientific Affairs, participated in an Institute of Medicine (IoM) workshop, titled “Conflict of Interest in Medical Innovation: Assuring Integrity while Facilitating Innovation in Medical Research.” Gabriela presented on the impact o